Short answer
Cogent Biosciences, Inc. (COGT) filed its Q3 2025 10-Q quarterly report on Nov 7, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$81M
- −14.6% YoY · −10.1% QoQ
- EPS (diluted)
- −$0.50
- +21.9% YoY · +5.7% QoQ
Source: XBRL data from the Cogent Biosciences, Inc. (COGT) Q3 2025 10-Q on SEC EDGAR. USD.
Cogent Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New financing risk due to $400M Credit Facility with SLR, $75M tranche contingent on positive Phase 3 PEAK data
- Updated covenant risk includes restrictive terms limiting operations, acquisitions, and licensing under Loan and Security Agreement
- Regulatory/legal risk tied to possible acceleration of $400M debt repayment upon defaults, including financial covenant breaches or bankruptcy
- Operational risk from milestone-dependent tranche releases, with failure to meet milestones risking restricted fund access and refinancing needs
- Financial risk from June 1, 2030 debt maturity requiring refinancing; limited cash flow may impair debt servicing and liquidity management
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cogent Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.